Yahoo · Aug 10, 2026
5 Stocks With Recent Price Strength to Tap August Rally
Five stocks, including OPHC, EDRY, ENVA, ANIK and GEO, show strong recent price gains and earnings growth as markets rally.
AN
NASDAQ · ANIK
Anika Therapeutics, Inc.
Healthcare · Medical - Devices
$20.84
Down-$0.84 (-3.87%)
Updated Aug 28, 2026, 9:02 AM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 207.09M
- P/E ratio
- -18.84
- Dividend yield
- 0.00%
- 52-week range
- $8.37 – $22.88
- Volume
- 171.47K
- Avg. volume
- 156.61K
Price performance
ANIK price history
1M range · 21 trading sessions · Daily adjusted prices
ANIK closed at $20.84 after 21 trading sessions, up 15.33% for the selected period.
- Last close
- $20.84
- Period change
- +15.33%
- Period low
- $18.07
- Period high
- $22.03
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $21.51 | $21.97 | $20.80 | $20.84 | 171.47K |
| Aug 26, 2026 | $21.29 | $21.7999 | $20.845 | $21.68 | 90.15K |
| Aug 25, 2026 | $21.43 | $21.9189 | $21.35 | $21.40 | 73.46K |
| Aug 24, 2026 | $22.35 | $22.525 | $21.13 | $21.34 | 124.76K |
| Aug 21, 2026 | $21.38 | $22.32 | $21.0101 | $21.78 | 340.43K |
| Aug 20, 2026 | $21.15 | $21.65 | $21.10 | $21.34 | 89.34K |
| Aug 19, 2026 | $21.88 | $22.05 | $21.25 | $21.26 | 80.21K |
| Aug 18, 2026 | $21.48 | $21.98 | $21.0936 | $21.57 | 87.03K |
| Aug 17, 2026 | $21.21 | $21.99 | $20.74 | $21.47 | 121.23K |
| Aug 14, 2026 | $21.17 | $21.98 | $21.035 | $21.50 | 124.99K |
| Aug 13, 2026 | $22.05 | $22.4213 | $21.035 | $21.17 | 102.07K |
| Aug 12, 2026 | $21.23 | $22.23 | $20.4196 | $22.03 | 141.05K |
| Aug 11, 2026 | $20.59 | $21.64 | $20.54 | $21.23 | 114.21K |
| Aug 10, 2026 | $21.93 | $22.88 | $20.61 | $20.68 | 125.99K |
| Aug 7, 2026 | $20.60 | $21.55 | $20.09 | $21.42 | 183.57K |
| Aug 6, 2026 | $19.40 | $20.3899 | $19.40 | $20.16 | 193.2K |
| Aug 5, 2026 | $19.64 | $19.68 | $19.00 | $19.19 | 95.16K |
| Aug 4, 2026 | $20.57 | $20.75 | $18.98 | $19.61 | 238.77K |
| Aug 3, 2026 | $19.59 | $21.115 | $19.59 | $20.735 | 183.25K |
| Jul 31, 2026 | $18.33 | $19.29 | $17.87 | $19.28 | 170.49K |
| Jul 30, 2026 | $16.51 | $18.58 | $16.5006 | $18.07 | 114.43K |
Latest ANIK news
The latest Smart Investors Daily articles mentioning ANIK.
Stock researchCompany · Overview
ANIK research
Overview
Company profile and research snapshot.
Company profile
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 30, 2026 | B. Riley Securities | Buy | — |
| Feb 27, 2026 | Barrington Research | Outperform | — |
| Jan 9, 2026 | Barrington Research | Outperform | — |
| Nov 6, 2025 | Barrington Research | Outperform | — |
| Sep 23, 2025 | Barrington Research | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 8, 2026
Anika (ANIK) Q2 2026 Earnings Call Transcript
Revenue hit $32.6 million with record commercial channel sales and expanded margins.
Yahoo · Aug 7, 2026
Anika (ANIK) is on the Move, Here's Why the Trend Could be Sustainable
Anika (ANIK) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Yahoo · Aug 2, 2026
Anika Therapeutics (ANIK) Stock Fair Value Rises After Q2 Beat And Higher Guidance
The latest analyst update on Anika Therapeutics centers on a higher price target, with modeled fair value moving from US$16 to US$21 per share. Research commentary describes this shift as a reflection of greater confidence in the company’s ability to sustain profitability, supported by the recent Q2 beat, stronger margins, and raised guidance. As you read on, you will see how this evolving narrative is taking shape and what to watch to stay in step with it. Stay updated as the Fair Value for...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
